Boston Scientific Corporation
817
81
123
521
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
12.5%
102 terminated/withdrawn out of 817 trials
83.6%
-2.9% vs industry average
14%
116 trials in Phase 3/4
60%
314 of 521 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (817)
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Role: lead
Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device
Role: lead
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
Role: lead
TheraSphere With Durvalumab and Tremelimumab for HCC
Role: lead
RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)
Role: lead
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
Role: lead
Treatment of Focal Ventricular Tachycardias Using a Pulsed Field Ablation From a Point Ablation Catheter Short Title FOCUS-PFA
Role: collaborator
OverStitch NXT Endoscopic Suture System
Role: lead
FARAPULSE™ Pulsed Field Ablation System
Role: lead
A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation
Role: lead
A Post-Approval, Single-Arm Study of the SYNERGY Stent System in China
Role: lead
Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365')
Role: lead
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
Role: collaborator
A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation
Role: lead
FARAPULSE Workflow Assessment Registry
Role: lead
Feasibility Study of the FARAFLEX Mapping and PFA System
Role: lead
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
Role: lead
The COMBINE-AF Trial
Role: collaborator
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Role: lead
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation
Role: lead